Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...

The most commonly used GLP-1 receptor agonist was semaglutide (Ozempic, Wegovy, Rybelsus; 42.9%), followed by dulaglutide (Trulicity; 38.7%), liraglutide (Victoza, Saxenda; 15.9%), and exenatide ...

Novo Nordisk, for its part, markets an oral version of its GLP-1 semaglutide as Rybelsus, though the drug is only approved in type 2 diabetes. Meanwhile, Evercore ISI analyst Umer Raffat said he ...

As reported on August 27, 2024, Lexaria has already demonstrated in human testing, delivery superiority to the world's ONLY existing orally dosed GLP-1 drug, Rybelsus® (semaglutide), owned by ...

Web Exclusive How Antiobesity Drugs Are Linked to Food Waste. Taking antiobesity drugs has led some US adults to throw away more food than they tossed before starting the medicati ...

The specialty pharmacy business may be the most attractive part of Walgreens as rumors swirl the company will be taken over ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Viking Therapeutics inks broad manufacturing pact with CordenPharma to support commercialization of VK2735: San Diego Wednesday, March 12, 2025, 17:00 Hrs [IST] Viking Therapeutic ...

According to Forbes, Semaglutide, a market leader for obesity drugs and the generic version of Ozempic, Wegovy, and Rybelsus, was the most prescribed Glucagon-Like Peptide-1 GLP-1 agonist in 2023.